• CEO Dr. Sudhir Srivastava, in a recent interview with The Motley Fool, that SS Innovations has performed more than 15,000 procedures using its SSi Mantra robotic surgical systems, including approximately 750 cardiac procedures.
  • In addition, more than 200 telesurgeries have been performed using the platform, including 27 cardiac procedures, as the company explores ways to extend specialist surgical expertise to underserved communities.
  • Srivastava highlighted the SSi Mantra’s differentiated engineering, including its 4K 3D visualization, surgeon-controlled anatomical imaging and modular design supporting up to five robotic arms.
  • SS Innovations is preparing to expand its Indian manufacturing capacity through a planned 10-acre facility, with the objective of bringing additional production capabilities in-house.
  • Regulatory applications in Europe and the United States are also progressing, with management targeting international expansion through direct sales and opportunities in ambulatory surgery centers.
  • The company is experiencing strong commercial momentum, with first-half 2026 revenue increasing approximately 66% year-over-year to about $25 million.

During the interview, Srivastava said the company had performed more than 15,000 procedures using its robotic systems, including approximately 750 cardiac surgeries. He also highlighted the platform’s expanding use across multiple…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.